

Supporting Information

Bras et al. 10.1073/pnas.1117317109




Fig. S1. *mlf* is expressed in larval crystal cells. Immunostaining against MLF (A and B) or β -galactosidase (*mlf-lacZ*) (C and D) on third instar larval lymph glands (A and C) or circulating blood cells (B and D). Crystal cells are labeled by GFP (*Iz-Gal4*, *UAS-GFP*). (Insets, A and C) Higher-magnification views of LZ-GFP⁺ cells.




Fig. S2. *mlf* expression is activated by SRP/LZ in *Drosophila*. Lateral views of stage 11 embryos showing *mlf* expression as revealed by in situ hybridization. (A–D) Expression of the indicated *UAS* transgenes was driven in the mesoderm under the control of *twi-Gal4*. *twi-Gal4*-driven ectopic coexpression of SRP and LZ induces *mlf* transcription throughout the mesoderm.




Fig. S3. *mlf* mutation does not impair embryonic plasmatocyte development. In situ hybridization against *pxn* was used to monitor plasmatocyte differentiation in WT (A) and *mlf* mutant (B) stage 16 embryos. (Upper) Lateral views. (Lower) Dorsal views.




Fig. S6. MLF stabilizes LZ and RUNX1-ETO protein levels in vivo. (A) Fluorescent immunostaining against LZ was used to monitor LZ expression levels in circulating larval blood cells from *lz-Gal4*, *UAS-GFP* third instar larvae of the indicated genotype. (B) Fluorescent immunostaining against RUNX1-ETO was used to assess RUNX1-ETO expression levels in circulating larval blood cells from *lz-Gal4*, *UAS-GFP*; *UAS-RUNX1-ETO* (control) or *lz-Gal4*, *UAS-GFP*; *mlf^{Δ5-3}/mlf^{Δ5-3}*; *UAS-RUNX1-ETO* (*mlf^{Δ5-3}/mlf^{Δ5-3}*) third instar larvae. Fluorescent intensities were measured using ImageJ software on a minimum of 15 LZ-GFP⁺ cells of each genotype. *** $P < 0.0001$, Student *t* test.